REVIEW 1 cited by
Modality Dropout for Improved Performance-driven Talking Faces
Not yet reviewed by Pith; the record is open.
This paper has not been read by Pith yet. Machine review is queued; the pith claim, tier, and objections will appear here once it completes.
SPECIMEN: schema-true, not a live event
T0 review · schema-true
One-sentence machine reading of the paper's core claim.
pith:XXXXXXXX · record.json · timestamp
read the original abstract
We describe our novel deep learning approach for driving animated faces using both acoustic and visual information. In particular, speech-related facial movements are generated using audiovisual information, and non-speech facial movements are generated using only visual information. To ensure that our model exploits both modalities during training, batches are generated that contain audio-only, video-only, and audiovisual input features. The probability of dropping a modality allows control over the degree to which the model exploits audio and visual information during training. Our trained model runs in real-time on resource limited hardware (e.g.\ a smart phone), it is user agnostic, and it is not dependent on a potentially error-prone transcription of the speech. We use subjective testing to demonstrate: 1) the improvement of audiovisual-driven animation over the equivalent video-only approach, and 2) the improvement in the animation of speech-related facial movements after introducing modality dropout. Before introducing dropout, viewers prefer audiovisual-driven animation in 51% of the test sequences compared with only 18% for video-driven. After introducing dropout viewer preference for audiovisual-driven animation increases to 74%, but decreases to 8% for video-only.
Forward citations
Cited by 1 Pith paper
-
Negative to Positive Co-learning with Aggressive Modality Dropout
Applying 80% modality dropout to audio and video features during training reversed negative co-learning on IEMOCAP, lifting unimodal test accuracy from 27% to 47% and beating the unimodal baseline.
Discussion (0). Continue with ORCID to comment.